NANOLOGIX IS A BIOTECHNOLOGY COMPANY specializing in rapid diagnostics tools for biodefense, medical, environmental, and industrial uses.
The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.
Stock Symbol NNLX.pk
Our BNP™ ultra-fast test kit sets a new standard for accurate, high-speed diagnostics. With results two to four times faster than traditional Petri dish methods, NanoLogix technology represents a revolutionary next step in microorganism identification.
Uses for NanoLogix’s very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.
NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
See the Products page to explore our new BNP™ technology.
Please contact us for more information.
TIME TO DETECTION
Comparison of BNP™ with traditional petri dish technology
| Microorganism | Traditional time range for observance of cultures (hours) | Average time with BNP™ (hours)* |
|---|---|---|
| Bacillus anthracis | 24 | 6* |
| Yersinia pestis | 48 | 24* |
| Salmonella enterica | 24 | 5* |
| Escherichia coli | 18 - 24 | 4* |
| Staphylococcus aureus | 18 - 24 | 4* |
| Pseudomonas aeruginosa | 18 - 24 | 5* |
| Streptococcus pyogenes | 18 - 24 | 5* |
| Assorted yeasts | 48 - 72 | 12 - 16* |
| Entherobacter cloaceae | 24 | 5 - 6* |
| Listeria inocula | 18 - 24 | 5* |
| Klebsiella pneumonia | 24 | 6* |
*"Average time with BNP™" results are based upon results actually achieved by NNLX through internal testing or results reported from independent third party tests. Detection time depends upon environmental conditions, sample quality, microorganism growth rates, nutrient concentrations, and many other factors. Actual results may vary.
Update
Wednesday, August 25, 2010
The company has been issued U.S. patent #7,781,159 for its invention of a method and device for the rapid detection, enumeration and identification of microorganisms. This is one of two foundational patents granted this year for our BioNano technologies.
Monday, August 23, 2010
EPA AND NANOLOGIX ENTER INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR RAPID WATER QUALITY TESTING
Hubbard, OH (Marketwire – 08/23/10) - NanoLogix, Inc. (Pinksheets:NNLX - News) The U.S. Environmental Protection Agency announced it has entered into a Cooperative Research and Development Agreement (CRADA) with NanoLogix.
Friday, August 20, 2010
NanoLogix featured in this month’s issue of Medical Design Technology magazine, Speeding Up Petri Dish Diagnostics. “Petri dish technology is used around the world and the sandwiched-membrane BioNanoPore (BNP) test kits hold the potential to change diagnostics across the board."
Friday, August 20, 2010
NanoLogix BNF technology highlighted in ADVANCE for Administrators of the Laboratory, NanoLogix and UT Medical Center Shorten Wait Times for Group-B Streptococcus Tests. “ NanoLogix Inc. offers its BNF technology in controlled testing at the University of Texas-Texas Medical Center in Houston for the bacteria Group B Streptococcus (GBS) in pregnant women."
Wednesday, June 30, 2010
NanoLogix has filed and received medical device registration approval from the U.S. FDA for their BNP™ BNF™ and BNC™ test kits. Registration number: 3005553828.
Tuesday, June 22, 2010
Our collaboration with the Texas Medical Center has produced preliminary culture-based results for the rapid detection of Group-B Streptococcus of between 4-6 hours. The initial results are 12-18 times faster than the 72 hour wait time experienced with traditional petri technology. The Texas Medical Center is continuing to finalize these Group-B Strep results and NanoLogix is furnishing additional test kits for that purpose.